FRIDAY, Nov.

 A Redland Bay couple who lost their six-year-old son to Pulmonary Hypertension (PH) five months ago are "over the moon" they helped raise awareness of the deadly disease while participating in the Gatorade Tri-Series at Raby Bay.

 Pulmonary hypertension which can lead to congestive heart failure may be a thing of the past according to new research.  On November 3rd the American Heart Association journal Circulation, published findings by Dr.

 n a groundbreaking discovery, researchers at the Unversity of California, San Diego, have identified a key protein that promotes the development of pulmonary arterial hypertension in humans and mice.

 A pensioner has defied the odds to live over two decades after a heart and lungs transplant.

 ScienceDaily (Oct. 26, 2009) — Researchers at the University of California, San Diego, have identified a key protein that promotes the development of pulmonary arterial hypertension in humans and mice.

 Actelion Launches Increased Strength Formulation of Ventavis (Iloprost) for

Pulmonary Arterial Hypertension in the United States

SOUTH SAN FRANCISCO, Calif., Sept. 1 /PRNewswire/ -- Actelion Pharmaceuticals
US, Inc., today announced the first commercial sales of a new 20 microgram per
milliliter (mcg/mL) formulation of Ventavis(R), for the treatment of New York

 The day before Mother's Day this year, Redland Bay mother Vivienne McGrath lost her six-year-old son Alex to Pulmonary Hypertension (PH).

PH is a rare, life-threatening lung disease where the sufferer's blood pressure in the arteries of their lungs elevates.

This places stress on the heart and reduces the amount of oxygen that is able to reach tissues of the body.

Pfizer Australia announced that it has signed an agreement to acquire the local distribution rights for THELIN® (Sitaxentan sodium), an oral, once-daily highly selective endothelin receptor antagonist, indicated for the treatment of pulmonary arterial

 Oxygen levels while flying are substantially less than at ground level. Current guidelines for in-flight oxygen levels are sufficient to support the needs of passengers with non-obstructed lung disease. According to two new articles commercial air travel appears to be safe for patients with lung disease as the current policies for the in-flight oxygen levels and availability of supplemental oxygen can adequately accommodate passenger's needs.